Tuesday, July 25, 2017 9:54:35 PM
GNCA (T/$12-40) ....THIS IS A $6 STOCK today...Cowen analyst Phil Nadeau is out with a bullish note on shares of Genocea Biosciences Inc (NASDAQ:GNCA), reiterating an Outperform rating with a $40 price target, which implies an upside of 586% from current levels.
(IF you can get a good entry price...you will have plenty of opportunity to play this and accumulate shares...just remember that there is no such thing as a sure thing...this is a game so play it like a game until the news becomes real with FDA approval...until then its HYPE...Swing Trade the hell out of it...buy low sell high...)...for now its a $6 stock that has $10 on its mind (...0r does it...?...)...I like seeing how price acts at $4-5-6 and at $9-10-11...this is the life blood of a Swing Trader...the game should be fun...don't sale the farm...this is SPECULATION until "real" news happens...
Genocea Biosciences, lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus.
https://finance.yahoo.com/news/cowen-sings-praises-genocea-biosciences-211052793.html The reason? Genocea announced data from GEN-003 Phase 2b trial in HSV2 demonstrating significant reductions in several measures of genital lesions through 12 months. Nadeau commented, "We are optimistic that GEN-003 will succeed in Phase III, and think that it addresses a significant commercial opportunity. The CDC estimates that 16% of the U.S. population aged >14 has been infected with HSV-2 and that 20-25% of infected people are aware of their status. This implies that GEN-003 could address a market oppy of 8MM - 11MM people in the U.S. alone. Assuming a price of $300 per course, GEN-003's total addressable market would be $2B+."
(07/24) All the 5 analysts polled in the past 12 months rate Genocea stock a Buy. With a return potential of 323%, the stock's consensus target price stands at $24.67.
Daily chart has price overbought...I need to know how to act at the $6 level...
60 minute...chart is on a sell right now...
http://stockcharts.com/c-sc/sc?s=GNCA&p=60&yr=0&mn=1&dy=0&i=p75206172804&a=536436369&r=1501033987498
(IF you can get a good entry price...you will have plenty of opportunity to play this and accumulate shares...just remember that there is no such thing as a sure thing...this is a game so play it like a game until the news becomes real with FDA approval...until then its HYPE...Swing Trade the hell out of it...buy low sell high...)...for now its a $6 stock that has $10 on its mind (...0r does it...?...)...I like seeing how price acts at $4-5-6 and at $9-10-11...this is the life blood of a Swing Trader...the game should be fun...don't sale the farm...this is SPECULATION until "real" news happens...
Genocea Biosciences, lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus.
https://finance.yahoo.com/news/cowen-sings-praises-genocea-biosciences-211052793.html The reason? Genocea announced data from GEN-003 Phase 2b trial in HSV2 demonstrating significant reductions in several measures of genital lesions through 12 months. Nadeau commented, "We are optimistic that GEN-003 will succeed in Phase III, and think that it addresses a significant commercial opportunity. The CDC estimates that 16% of the U.S. population aged >14 has been infected with HSV-2 and that 20-25% of infected people are aware of their status. This implies that GEN-003 could address a market oppy of 8MM - 11MM people in the U.S. alone. Assuming a price of $300 per course, GEN-003's total addressable market would be $2B+."
(07/24) All the 5 analysts polled in the past 12 months rate Genocea stock a Buy. With a return potential of 323%, the stock's consensus target price stands at $24.67.
Daily chart has price overbought...I need to know how to act at the $6 level...
60 minute...chart is on a sell right now...
http://stockcharts.com/c-sc/sc?s=GNCA&p=60&yr=0&mn=1&dy=0&i=p75206172804&a=536436369&r=1501033987498
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
